Developing Cyclic Peptomers as Broad-Spectrum Type III Secretion System Inhibitors in Gram-Negative Bacteria
Open Access
- 17 June 2021
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (7)
Abstract
Antibiotic resistant bacteria are an emerging global health threat. New antimicrobials are urgently needed. The injectisome type III secretion system (T3SS), required by dozens of Gram-negative bacteria for virulence but largely absent from non-pathogenic bacteria, is an attractive antimicrobial target. We previously identified synthetic cyclic peptomers, inspired by the natural product phepropeptin D, that inhibit protein secretion through the Yersinia Ysc and Pseudomonas aeruginosa Psc T3SSs, but do not inhibit bacterial growth. Here we describe identification of an isomer, 4EpDN, that is two-fold more potent (IC50 of 4 μM) than its parental compound. Furthermore, 4EpDN inhibited the Yersinia Ysa and the Salmonella SPI-1 T3SSs, suggesting that this cyclic peptomer has broad efficacy against evolutionarily distant injectisome T3SSs. Indeed, 4EpDN strongly inhibited intracellular growth of Chlamydia trachomatis in HeLa cells, which requires the T3SS. 4EpDN did not inhibit the unrelated Twin arginine translocation (Tat) system, nor did it impact T3SS gene transcription. Moreover, although the injectisome and flagellar T3SSs are evolutionarily and structurally related, the 4EpDN cyclic peptomer did not inhibit secretion of substrates through the Salmonella flagellar T3SS, indicating that cyclic peptomers broadly but specifically target the injestisome T3SS. 4EpDN reduced the number of T3SS needles detected on the surface of Y. pseudotuberculosis as detected by microscopy. Collectively, these data suggest that cyclic peptomers specifically inhibit the injectisome T3SS from a variety of Gram-negative bacteria, possibly by preventing complete T3SS assembly.Keywords
All Related Versions
Funding Information
- HHS | National Institutes of Health (K99AI139281)
- HHS | National Institutes of Health (R01AI141511)
This publication has 115 references indexed in Scilit:
- Chemical Inhibitors of the Type Three Secretion System: Disarming Bacterial PathogensAntimicrobial Agents and Chemotherapy, 2012
- Quantitative proteomics reveals metabolic and pathogenic properties of Chlamydia trachomatis developmental formsMolecular Microbiology, 2011
- Identification of Bacterial Target Proteins for the Salicylidene Acylhydrazide Class of Virulence-blocking CompoundsJournal of Biological Chemistry, 2011
- Identification and Characterization of Small-Molecule Inhibitors of Yop Translocation in Yersinia pseudotuberculosisAntimicrobial Agents and Chemotherapy, 2010
- Deciphering the assembly of the Yersinia type III secretion injectisomeThe EMBO Journal, 2010
- Discovery and Characterization of Inhibitors of Pseudomonas aeruginosa Type III SecretionAntimicrobial Agents and Chemotherapy, 2010
- N-Hydroxybenzimidazole Inhibitors of the Transcription Factor LcrF in Yersinia: Novel Antivirulence AgentsJournal of Medicinal Chemistry, 2009
- An Inhibitor of Gram-Negative Bacterial Virulence Protein SecretionCell Host & Microbe, 2008
- Actin and Intermediate Filaments Stabilize the Chlamydia trachomatis Vacuole by Forming Dynamic Structural ScaffoldsCell Host & Microbe, 2008
- A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatisProceedings of the National Academy of Sciences, 2006